This morning I sit quietly in my hotel room, contemplating the day ahead at the 2013 Heart Rhythm Society Scientific Sessions in Denver. Emotions clash.
Conference coverage
HRS 2013: St. Jude Medical touts independent safety data for next-gen Durata leads
Medical device giant St. Jude Medical (NYSE:STJ) landed an important win today after a research team released study results finding that the company’s Durata defibrillator leads proved safe and reliable in an independent review.
Looking back on a pretty sedate ACC
Sometimes the major annual medical meetings are jam-packed with significant and market-moving data. And then sometimes they’re like this year’s American College of Cardiology conference, with relatively limited useful data from an investing perspective.
What’s going on in orthopedics? A chat with Biomet CEO Jeff Binder
Next week, the eyes of the orthopedic world turn to Chicago for the annual meeting of the American Academy of Orthopaedic Surgeons.
Study: Renal denervation for hypertension may also help stabilize heart rhythms
Renal denervation technologies, which are already the focus of much clinical attention for the potential to treat high blood pressure without drugs, may have a bonus side-effect in keeping the heart in check, according to researchers.
Covidien Ventures’ Amy Belt discusses the origins of Medtech Women
This article is an excerpt from a blog post originally published on biodesignalumni.com
Why do women rarely headline medtech conferences?
Amy Belt, Director, Covidien Ventures, pondered this question in the spring of 2009, looking out to a sea of navy blue blazers and calculating only 4% of the podium speakers at her 3 > previous conferences were women.
TAVI: Sapien going strong at 3 years, but leak risk remains “overwhelmingly” higher
Updated March 19, 2013, at 11:30 a.m. to reflect that the quote in paragraph 6 came from an ACC press release, not an Edwards press release.
ACC defends cancellation as docs lament missing Boston Scientific presentation | MassDevice.com On Call
MASSDEVICE ON CALL — The embargo breach that got Boston Scientific’s (NYSE:BSX) PREVAIL clinical trial results pulled from the lineup at the American College of Cardiology conference this weekend was "an honest mistake," according to the company, but conference organizers don’t regret canceling the presentation.
Hauser’s FDA Rx: The FDA needs an NTSB
Dr. Robert Hauser hopes to push a major change at the FDA, looking to shift the monitoring of medical devices and drugs that are already on the market from the FDA to an independent entity.
Hauser, a long-time patient safety advocate and vocal FDA critic, is aiming to sell Capitol Hill on a new structure for the U.S. healthcare regulation system akin to how the nation deals with transportation safety, he told MassDevice.com in an exclusive interview.
Early results “encouraging” for Edwards’ redesigned Sapien XT valve
Boston Scientific apologizes for embargo breach that got its Watchman trial pulled from conference
Updated March 9, 2013, at 8:30 p.m. PST with comment, slides from Boston Scientific.